The reduction of PHLDA3 protein levels in ALS ACM led to a 1.24-fold (P = 0.031) decrease in ROS levels when compared with ACM of non-treated ALS astrocytes that were comparable to scr siRNA-treated ALS astrocytes (P = 0.51), while their viability was unaffected (ANOVA P = 0.379; Fig. 4E). This evidence concerns the gene PHLDA3 and amyotrophic lateral sclerosis.